Luke Sheridan Rains publishes his debut blog on a recent multicentre RCT of Cannabidiol (CBD) as an adjunctive therapy for people with schizophrenia, which suggests that CBD had a beneficial, but modest impact on positive psychotic symptoms and severity of illness when used alongside existing antipsychotics.